| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2972611 | The Journal of Heart and Lung Transplantation | 2008 | 4 Pages |
Abstract
There was a high incidence of CMV disease in D+/Râ heart transplant recipients despite CMV hyperimmune globulin, 2 weeks of intravenous ganciclovir and 3 months of valganciclovir prophylaxis. CMV infection occurred consistently within 2 to 3 months of cessation of valganciclovir. Alternative strategies for CMV prophylaxis, including an extension of valganciclovir prophylaxis to 6 months after heart transplantation, needs to be investigated.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Sachin MD, Joshua D. BS, David W. MD, Pradeep P.A. MD, Parag C. MD, Patricia RN, W. Steves MD, J. Michael MD, Mark H. MD, MSc,